Ideaya Biosciences, Inc. IDYA

What this company does

IDEAYA Biosciences, Inc. is a precision medicine oncology company engaged in the discovery, development and commercialization of therapies for cancer. Its clinical pipeline includes nine product candidates organized across four clinical focus areas: darovasertib for uveal melanoma, antibody-drug conjugate and DNA damage response combinations, the MTAP pathway, and next generation therapies. Darovasertib, an oral small molecule inhibitor of protein kinase C, is the most advanced program in the pipeline and is being developed for uveal melanoma, a form of ocular cancer in which approximately 95% of patients carry activating mutations in GNAQ/11 GTPase proteins. As of December 31, 2025, the company had a total of 145 employees, of whom 112 were engaged primarily in research and development activities and 33 in general and administrative activities. The company was founded in June 2015 as a Delaware corporation and maintains its principal executive offices in South San Francisco, California.

Written from the business description in IDEAYA Biosciences, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.